CJ Bio has officially launched Facetem, a calcium hydroxyapatite (CaHA)-based collagen booster, in Thailand in partnership with BJC, a leading distribution and healthcare company. The move strengthens CJ Bio's foothold in Southeast Asia's growing medical aesthetics market and offers overseas buyers a new regenerative injectable option through an established local channel.
Launch event and partnership
CJ Bio held an official launch event in Thailand on June 9 for Facetem, its CaHA-based collagen booster, in collaboration with BJC. BJC is a major distribution and healthcare company in Thailand, providing CJ Bio with access to a well-established medical aesthetics network. The partnership aims to begin product supply and ramp up academic marketing activities in the Thai market.
Product background and global footprint
Facetem is the global brand name for CJ Bio's CaHA-based collagen booster. In Korea and Indonesia, the same product is marketed under the brand name Declasy. The product is currently exported to more than 32 countries worldwide and has become the second-largest brand by market share in the global CaHA market, positioning it as a leading product in the regenerative aesthetics field.
CEO statement on market strategy
Hyunseung Yoo, CEO of CJ Bio, stated, "As the second-largest brand in the global CaHA market, we will continue to expand academic activities and clinical data in the Thai market, leveraging our accumulated clinical experience, product competitiveness, and BJC's strong local network."
Sourcing context
For overseas distributors and clinic buyers, this launch signals CJ Bio's commitment to expanding its CaHA product line in Southeast Asia. The partnership with BJC provides a reliable channel for procurement in Thailand. Buyers in other markets may watch for similar distribution deals as CJ Bio continues to grow its global CaHA market share.
Source: Read the original report | Published: June 09, 2026